Biotech’s Next Era: Data, AI and the Future of Decision-Making with Jay Roberts
In this episode of Clinical Trial Blazers, host Alberto Grignolo speaks with veteran biotech executive, investor, and board member Jay Roberts about his journey from CFO to CEO and the leadership lessons that shaped his career. Jay explains how a foundation in finance prepared him to lead biotech companies through clinical uncertainty, capital challenges, and high-stakes decision-making, while emphasizing the importance of building strong teams, making fact-based decisions, and knowing when to pivot, partner, or stop a program. He also shares his perspective on investor expectations, board governance, the evolving role of AI and data in drug development, and the qualities tomorrow's biotech leaders will need to successfully bring innovative therapies to patients.
Related Insights
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
The essential role of translation in early phase neurology research
Jun 18, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026
Related Insights
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
CTB Webinar
Rethinking Phase I: Five strategies for faster proof of concept
Aug 4, 2026
CTB Podcast
A Journey through Academia, Big Pharma and Biotech: Building Breakthrough Medicines with Dr. Briggs Morrison
Aug 3, 2026
CTB Blog
Leveraging early-phase ethnobridging to reduce drug lag in China and Japan
Jul 15, 2026
CTB Blog
Modeling & simulation and artificial intelligence for early drug development
Jul 14, 2026
CTB Podcast
Overcoming Hurdles in Rare Disease Therapy with Reenie McCarthy
Jul 6, 2026
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
CTB Blog
In early phase trials, operations is where speed is won or lost
Jun 28, 2026
CTB Blog
A credible global regulatory strategy is an early-phase imperative, not a late-stage commercial exercise
Jun 23, 2026
CTB Blog
The essential role of translation in early phase neurology research
Jun 18, 2026
CTB Blog
Understanding FDA complete response letters: Why CMC readiness must become a strategic priority
Jun 18, 2026